Fortress Biotech's Cyprium enters agreement to sell PRV for $205M [Yahoo! Finance]
Fortress Biotech (NASDAQ:FBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]